Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy

(2013) Jenny Klintman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

(2013) A. Tiede et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

(2013) M. J. Manco-Johnson et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII Products and Inhibitor Development in Severe Hemophilia A

(2013) Samantha C. Gouw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

(2012) J. A. Dumont et al.   BLOOD

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

(2012) S. F. J. Whelan et al.   BLOOD

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

(2012) S. C. Gouw et al.   BLOOD

Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A

(2012) J. Klintman et al.   HAEMOPHILIA

Clinical trial design in haemophilia

(2012) D. M. DIMICHELE et al.   HAEMOPHILIA

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein

(2012) R. T. PETERS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity

(2011) C. H. MILLER et al.   HAEMOPHILIA

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

(2011) L. A. VALENTINO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Improvements in factor concentrates

(2010) David Lillicrap   CURRENT OPINION IN HEMATOLOGY

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

(2009) M. RECHT et al.   HAEMOPHILIA

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

(2009) V. TERRAUBE et al.   HAEMOPHILIA

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

(2008) L. Gallinaro et al.   BLOOD

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype

(2008) M. Margaglione et al.   HAEMATOLOGICA